Ottimo Pharma
Robert Tighe is a seasoned professional in the field of preclinical and translational sciences, currently serving as Senior Vice President at Ottimo Pharma since February 2025. Prior to this role, Tighe was the Chief Scientific Officer at Ankyra Therapeutics from July 2023 to February 2025. Tighe's experience includes roles as Vice President of Research and VP of Translational Research at TCR² Therapeutics Inc. from July 2019 to June 2023, and Vice President of Translational Immunology & Immunopharmacology at Compass Therapeutics LLC from December 2015 to June 2019. Tighe's earlier career includes significant positions at EMD Serono, Inc., ArQule, The Jackson Laboratory, MIT, and the Whitehead Institute, contributing to advancements in immunology and gene therapy, including co-authoring a notable Science article on sickle cell anemia treatment.
This person is not in any teams
This person is not in any offices
Ottimo Pharma
Ottimo Pharma is a private biotechnology company, co-founded in 2020 by Medicxi and Jonny Finlay, focused on the development of pioneering innovative cancer therapies for solid tumors. The Company's lead program, Jankistomig, is a PD1-VEGFR2 bi-functional antibody designed to target both immune checkpoint inhibition and angiogenesis in a single IgG therapy. By advancing this dual-pathway approach, Ottimo Pharma aims to improve cancer treatment outcomes and reduce overall healthcare burden. The Company boasts a world-class leadership team, including David Epstein as Chair and CEO, Mehdi Shahidi as Head of Development and CMO, and James Sabry as Vice-Chair of the Board. Ottimo Pharma anticipates filing an IND in late 2025.